Acerta Pharma BV
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-35
RECRUITING0
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO91%
Delay Index: of 11 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +49.0 months). See all sponsors →
Open Acerta Pharma BV on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Acalabrutinib (ACP-196) NCT02180724 |
P2 | Active, not recruiting | Waldenström Macroglobulinemia (WM) | 107 | 2019-10-01 (+49 mo) |
| ACP-196 NCT02586857 |
P1/2 | Active, not recruiting | Glioblastoma Multiforme | 24 | 2020-06-26 (+30 mo) |
| Acalabrutinib NCT02477696 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia | 533 | 2020-09-15 (+27 mo) |
| ACP-196 (acalabrutinib) NCT02717611 |
P2 | Active, not recruiting | Chronic Lymphocytic Leukemia | 60 | 2020-10-16 (+8 mo) |
| ACP-196 (acalabrutinib) NCT02213926 |
P2 | Active, not recruiting | Mantle Cell Lymphoma (MCL) | 124 | 2020-12-04 (+61 mo) |
| Acalabrutinib NCT02029443 |
P1/2 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 306 | 2021-07-15 (+66 mo) |
| Acalabrutinib (ACP-196) NCT02970318 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia | 310 | 2021-09-03 (+20 mo) |
| acalabrutinib NCT02180711 |
P1/2 | Active, not recruiting | Non Hodgkin Lymphoma | 113 | 2023-08-25 (+96 mo) |
| Acalabrutinib NCT02972840 |
P3 | Active, not recruiting | Lymphoma, Mantle Cell | 635 | 2027-02-15 (+52 mo) |
| ESCALADE NCT04529772 |
P3 | Active, not recruiting | Diffuse Large B-Cell Lymphoma | 611 | 2027-02-22 (+6 mo) |
| AMPLIFY NCT03836261 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia | 984 | 2027-04-30 (+56 mo) |